MCI / AD Subtypes
SYNTap Test Capabilities
This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Specification Sheet
Identifying Lewy Body pathology at the MCI stage allows for a more personalized approach to disease management.
Ongoing studies indicate the need for early diagnosis and better definition of AD sub-types.
“Our results support a role for α-synuclein even in MCI, the early phase of AD, in addition to being a potential contributor in MCI and AD diagnosis or monitoring of disease progression.” (Ref.6)
Relevant Research Findings
“RT-QuIC (a research version of SAA) “identified patients with MCI-LB against cognitively unimpaired controls with 95% sensitivity, 97% specificity, and 96% accuracy and showed 98% specificity in neuropathologic controls.” (Ref.11)
Download the SYNTap Test Specification Sheet for details.
